NEXI (NexImmune) Other Current Payables: $0.00 Mil (As of Jun. 2024)


What is NexImmune Other Current Payables?

NexImmune NEXI Other Current Payables is $0.00 Mil as of Jun. 2024.

NexImmune's Other Current Payables for the quarter that ended in Jun. 2024 was $0.00 Mil.

NexImmune Other Current Payables Related Terms

NexImmune Other Current Payables Historical Data

* Premium members only.

The historical data trend for NexImmune's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NexImmune Other Current Payables Chart

NexImmune Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Payables
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

NexImmune Quarterly Data
Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NexImmune Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.00 Mil mean?
NexImmune (NEXI) has a Other Current Payables of $0.00 Mil as of Jun. 2024. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on NexImmune and its competitors.
Is NexImmune's Other Current Payables too high?
NexImmune's current Other Current Payables is $0.00 Mil.
How does NexImmune's Other Current Payables compare to PPCBD and ENDV?
NexImmune's Other Current Payables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on NexImmune and its competitors. NexImmune's current Other Current Payables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NexImmune stock overvalued right now?
NexImmune (NEXI) has a current Other Current Payables of $0.00 Mil. The current Other Current Payables is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For NexImmune (NEXI), the current Other Current Payables is $0.00 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NexImmune Business Description

Address 9119 Gaither Road, Gaithersburg, MD, USA, 20877
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.